Given the reduced expression of IGFBP3 in the C3.6 cells, IGFBP3's reported role in regulating IGF activity [35] and the reported aberrant regulation of the IGF system in breast cancer [36], we wanted to further examine if IGF1-induced signalling might be affected by ErbB2 overexpression in these cells. Here, ERBB2 is linked to breast cancer.